A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

Exclusion Criteria

• •Treatment with a biologic product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1
• •Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:
• •* Systemic corticosteroids
• •* Systemic immunosuppressants
• •* Phototherapy
• •* Janus kinase inhibitors
• •Treatment with any of the following medications or therapies within 1 week, prior to Day 1:
• •* TCS of any potency
• •* Topical calcineurin inhibitors (TCI)
• •* Topical Phosphodiesterase-4 inhibitors (PDE4)
• •* Other topical immunosuppressive agents
• •* Combination topical agents containing a corticosteroid or calcineurin inhibiting component, PDE4 inhibitors, or other topical immunosuppressive agents
• •Treatment with live virus including live attenuated vaccination 12 weeks prior to day 1 pre-randomization.
• •Treatment with any meningococcal vaccine within 1 year prior to screening, or treatment with any tetanus-, diphtheria-, or pertussis containing vaccine within 5 years prior to screening